Literature DB >> 18174385

Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.

Ankur Kapur1, Patrick Samaniego, Ganesh A Thakur, Alexandros Makriyannis, Mary E Abood.   

Abstract

Amino acid residues in the transmembrane domains of the CB(1) receptor are important for ligand recognition and signal transduction. We used site-directed mutagenesis to identify the role of two novel and adjacent residues in the transmembrane helix II domain, Ile2.62 and Asp2.63. We investigated the role of the conserved, negatively charged aspartate at position 2.63 in cannabinoid receptor (CB(1)) function by substituting it with asparagine (D2.63N) and glutamate (D2.63E). In addition, the effect of the mutant I2.62T alone and in combination with D2.63N (double mutant) on the affinity and potency of structurally diverse ligands was investigated. Recombinant human CB(1) receptors, stably expressed in human embryonic kidney 293 cells, were assayed for ligand affinity and agonist-stimulated guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding. The charge-conserved mutant D2.63E behaved similar to wild type. The charge-neutralization mutation D2.63N attenuated the potency of (-)-3-[2-hydroxyl-4-(1,1-dimethylheptyl)phenyl]-4-[3-hydroxylpropyl] cyclohexan-1-ol (CP,55940), (R)-(-)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)methanone (WIN55212-2), (-)-11beta-hydroxy-3-(1',1'-dimethylheptyl) hexahydrocannabinol (AM4056), and (-)-11-hydroxyldimethylheptyl-Delta(8)-tetrahydrocannabinol (HU210) for the stimulation of GTPgammaS binding, without affecting their binding affinities. Likewise, the I2.62T mutant selectively altered agonist potency without altering agonist affinity. It was surprising to note that the double mutant (I2.62T-D2.63N) displayed a drastic and synergistic increase (by approximately 50-fold) in the EC(50) for agonist-mediated activation. The profound loss of function in the I2.62T-D2.63N double mutant suggests that, although these residues are not obligatory for agonist recognition, they play a synergistic and crucial role in modulating signal transduction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174385      PMCID: PMC3767288          DOI: 10.1124/jpet.107.133256

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization.

Authors:  Aaron M D'Antona; Kwang H Ahn; Debra A Kendall
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

2.  Allosteric modulation of the cannabinoid CB1 receptor.

Authors:  Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2005-08-19       Impact factor: 4.436

Review 3.  Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity.

Authors:  Ya-Xiong Tao
Journal:  Mol Cell Endocrinol       Date:  2005-07-15       Impact factor: 4.102

4.  A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation.

Authors:  Aaron M D'Antona; Kwang H Ahn; Lei Wang; Dale F Mierke; Jean Lucas-Lenard; Debra A Kendall
Journal:  Brain Res       Date:  2006-07-31       Impact factor: 3.252

Review 5.  The MC4 receptor and control of appetite.

Authors:  R A H Adan; B Tiesjema; J J G Hillebrand; S E la Fleur; M J H Kas; M de Krom
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

Review 6.  International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Authors:  A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

7.  Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas.

Authors:  Ulrich Schüller; Arend Koch; Wolfgang Hartmann; Maria L Garrè; Cynthia G Goodyer; Armando Cama; Niels Sörensen; Otmar D Wiestler; Torsten Pietsch
Journal:  Int J Cancer       Date:  2005-10-20       Impact factor: 7.396

Review 8.  Regulation of thermogenesis by the central melanocortin system.

Authors:  Wei Fan; Adriana Voss-Andreae; Wei-Hua Cao; Shaun F Morrison
Journal:  Peptides       Date:  2005-10       Impact factor: 3.750

9.  Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects.

Authors:  Ya-Xiong Tao; Deborah L Segaloff
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

10.  Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation.

Authors:  Sean D McAllister; Dow P Hurst; Judy Barnett-Norris; Diane Lynch; Patricia H Reggio; Mary E Abood
Journal:  J Biol Chem       Date:  2004-08-23       Impact factor: 5.157

View more
  19 in total

Review 1.  Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Authors:  Haleli Sharir; Mary E Abood
Journal:  Pharmacol Ther       Date:  2010-03-16       Impact factor: 12.310

Review 2.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 3.  Cannabinoid receptors: nomenclature and pharmacological principles.

Authors:  Linda Console-Bram; Jahan Marcu; Mary E Abood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-28       Impact factor: 5.067

4.  Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.

Authors:  Robert B Laprairie; Abhijit R Kulkarni; Pushkar M Kulkarni; Dow P Hurst; Diane Lynch; Patricia H Reggio; David R Janero; Roger G Pertwee; Lesley A Stevenson; Melanie E M Kelly; Eileen M Denovan-Wright; Ganesh A Thakur
Journal:  ACS Chem Neurosci       Date:  2016-04-25       Impact factor: 4.418

Review 5.  CB1 and CB2 Receptor Pharmacology.

Authors:  Allyn C Howlett; Mary E Abood
Journal:  Adv Pharmacol       Date:  2017-06-12

6.  Distinct second extracellular loop structures of the brain cannabinoid CB(1) receptor: implication in ligand binding and receptor function.

Authors:  Joong-Youn Shim; James Rudd; Tomas T Ding
Journal:  Proteins       Date:  2011-02

7.  Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells.

Authors:  Kasem Nithipatikom; Ana Doris Gomez-Granados; Alan T Tang; Adam W Pfeiffer; Carol L Williams; William B Campbell
Journal:  Endocrinology       Date:  2011-11-15       Impact factor: 4.736

8.  Molecular basis of cannabinoid CB1 receptor coupling to the G protein heterotrimer Gαiβγ: identification of key CB1 contacts with the C-terminal helix α5 of Gαi.

Authors:  Joong-Youn Shim; Kwang H Ahn; Debra A Kendall
Journal:  J Biol Chem       Date:  2013-10-03       Impact factor: 5.157

9.  Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.

Authors:  Jahan Marcu; Derek M Shore; Ankur Kapur; Megan Trznadel; Alexandros Makriyannis; Patricia H Reggio; Mary E Abood
Journal:  J Pharmacol Exp Ther       Date:  2013-02-20       Impact factor: 4.030

10.  Transmembrane helical domain of the cannabinoid CB1 receptor.

Authors:  Joong-Youn Shim
Journal:  Biophys J       Date:  2009-04-22       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.